We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 20, 2022

Early B-Cell Repopulation in Patients With MS Treated With Rituximab Is Not Predictive of a Risk of Relapse or Clinical Progression

Journal of Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neurology
Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
J Neurol 2022 Jun 02;[EPub Ahead of Print], G Dorcet, H Migné, D Biotti, C Bost, F Lerebours, J Ciron, E Treiner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading